Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Calcium carbonate, Colecalciferol; cholecalciferol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Calcichew- D3 Once Daily are chewable tablets containing calcium and vitamin D3, which both are important substances in bone formation. Calcichew-D3 Once Daily is used in the prevention and treatment of calcium and vitamin D deficiency in adults with an identified risk of calcium and vitamin D deficiency, and as a supplement to specific treatment of osteoporosis. 2.
e Calcichew-D3 Once Daily
Do not take Calcichew-D3 Once Daily: if you are allergic to calcium, vitamin D, or any of the other ingredients of this medicine (listed in section 6). if you have severe kidney problems if you have excessive amounts of calcium in the blood or in the urine if you have kidney stones if you have excessive amounts of vitamin D in the blood. Warnings and precautions Talk to your doctor or pharmacist before taking Calcichew-D3 Once Daily if you are on long-term treatment, especially if you also take diuretics (used in treatment of high blood pressure or oedema) or cardiac glycosides (used to treat heart disorders). if you have signs of impaired renal function or high tendency of renal stone formation. if you have sarcoidosis (an immune system disorder which may cause increased levels of vitamin D in the body). if you have osteoporosis and at the same time are unable to move around. if you take other products containing vitamin D. Additional doses of calcium and vitamin D should be taken under close medical supervision. Children and adolescents Calcichew-D3 Once Daily is not intended for use in children and adolescents. Other medicines and Calcichew-D3 Once Daily 1
Tell your pharmacist if you are taking, or have recently taken or might take any other medicines. If you also take tetracyclines (a type of antibiotics), you should take these at least 2 hours before or 4-6 hours after intake of Calcichew-D3 Once Daily. Calcium carbonate may interfere with the absorption of tetracycline preparations if taken at the same time. Medicines containing bisphosphonates (used to treat osteoporosis) should be taken at least one hour before intake of Calcichew-D3 Once Daily. Calcium can reduce the effect of levothyroxine (used to treat thyroid deficiency). For this reason, levothyroxine should be taken at least four hours before or four hours after Calcichew-D3 Once Daily. The effect of quinolone antibiotics may be reduced if taken at the same time as calcium. Take quinolone antibiotics two hours before or six hours after taking Calcichew-D3 Once Daily. Calcium salts may decrease the absorption of iron, zinc and strontium ranelate. Consequently, iron, zinc or strontium ranelate preparations should be taken at least two hours before or after the calcium preparation. Other medicines that may influence or be influenced by Calcichew-D3 Once Daily are:
Calcichew-D3 Once Daily
Always take this medicine exactly as described in this leaflet or as your pharmacist has told you. Check with your pharmacist if you are not sure.
2
Dosage: The recommended dose is one tablet once daily. The tablet may be chewed or sucked. Use in children and adolescents Calcichew-D3 Once Daily is not intended for use in children and adolescents. If you take more Calcichew-D3 Once Daily than you should If you may have taken more Calcichew-D3 Once Daily than you should, talk to your pharmacist immediately. If you forget to take Calcichew-D3 Once Daily Do not take a double dose to make up for a forgotten tablet. If you have any further questions on the use of this medicine, ask your pharmacist. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Hypersensitivity reactions have occurred with unknown frequency (cannot be estimated from the available data). If you experience the following symptoms, you should immediately contact a doctor:
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.
Calcichew-D3 Once Daily
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month. Plastic Bottle: Do not store above 30°C. Store in the original container in order to protect from light. Keep the container tightly closed in order to protect from moisture. Blister: Do not store above 25°C. Store in the original package in order to protect from moisture. Keep blister in the outer carton in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
Content of the pack and other information
What Calcichew-D3 Once Daily contains The active substances in one tablet are: –
calcium carbonate 2500 mg (equivalent to 1000 mg calcium) colecalciferol (vitamin D3) 800 IU (20 microgram)
The other ingredients are xylitol (E967), povidone, isomalt (E953), flavouring (lemon), magnesium stearate, sucralose (E955), mono-and diglycerides of fatty acids, all-rac-alpha-tocopherol, sucrose, modified maize starch, medium chain triglycerides, sodium ascorbate and anhydrous colloidal silica (see also end of Section 2 'Calcichew-D3 Once Daily contains isomalt and sucrose'). What Calcichew-D3 Once Daily looks like and contents of the pack Calcichew-D3 Once Daily are white, round chewable tablets. May have small specks. Pack sizes: Plastic bottle with HDPE screw cap: 15, 30, 40, 60 and 90 tablets. Blister: 7, 14, 28, 50 x 1 (unit dose), 56, 84, 112, 140 and 168 tablets Not all pack sizes may be marketed. Marketing Authorisation Holder Neon Healthcare Ltd., 8 The Chase, John Tate Road, Hertford, SG13 7NN, UK Manufacturers Tablets packed in plastic bottles: Asker Contract Manufacturing AS Drammensveien 852 NO-1383 Asker Norway 4
or Takeda Pharma AS 55B Jaama Street, 63308 Polva Estonia Tablets packed in blister: Tjoapack Netherlands B.V. Nieuwe Donk 9, 4879 AC Etten-Leur, The Netherlands or Delpharm Novara S.r.L. Via Crosa 86 28065 Cerano (No), Italy This medicinal product is authorised in the Member States of the EEA under the following names: Austria: Cal-D-or 1000 mg/800 I.E. – Kautabletten Belgium: Steovit Forte citroen 1000 mg/800 I.E. kauwtabletten Czech Republic: Calcichew D3 Lemon 800 IU žvýkací tablety Germany: Calcimagon-D3 uno Greece: Calcioral D3® 1000 mg + 20 μg (800 IU) μασώμενο δισκίο Hungary: Calcichew-D3 1000 mg/800 NE rágótabletta Ireland: Calcichew-D3 Forte Double Strength 1000 mg / 800 IU Chewable Tablets Lithuania: Calcigran Forte 1000 mg / 800 TV kramtomosios tabletės Luxembourg: Steovit Forte citron 1000 mg/800 U.I. comprimés à croquer Netherlands: Calci-Chew D3 1000 mg/800 I.E., kauwtabletten Norway: Calcigran Forte 1000 mg/800 IE tyggetabletter Slovakia: Calcichew-D3 Citron 1000 mg/800 IU Spain: Mastical D Unidia 1000 mg/800 IU comprimidos masticables Sweden: Calcichew-D3 Citron 1000 mg/800 IE tuggtablett UK: Calcichew-D3 1000mg/800IU Once Daily Chewable tablets This leaflet was last revised in 03/2023. Additional Information Calcichew-D3 Once Daily are a combination of calcium and vitamin D designed to keep bones healthy. Calcium is an essential component of bones while vitamin D plays an important role in the absorption of calcium from food. Requirements for calcium increase with age and, although many people obtain enough calcium from their diet, some people may require a supplement in order that their body has all the calcium it needs to maintain healthy bones. Vitamin D is produced largely from the action of sunlight. Certain foodstuffs do contain vitamin D in reasonable amounts but it is not always possible to obtain all the vitamin D you need from your diet. People who do not get out and about, for instance those who are housebound or people living in nursing and residential homes, may not receive all the vitamin D they need. People with diets and lifestyles that mean they will obtain less than the recommended intake of calcium and vitamin D are at risk of weakened bones. Prolonged lack of adequate calcium and vitamin D intake can lead to the development of osteoporosis, a condition where bones become weak to a level that minimal trauma (for example, a fall) can result in a fracture, most typically at the hip, spine or wrist. 5
Calcichew-D3 Once Daily have been designed to give people whose intakes of calcium and vitamin D are low a boost to the recommended amounts. Maintaining healthy bones and helping to avoid osteoporosis is an important issue for many people. There are many ways that people can help themselves: regular exercise, a balanced diet with an adequate intake of calcium and vitamin D and, for some people, advice on how to prevent falls which may lead to fracture. For patients in the UK, the Royal Osteoporosis Society is a national charity dedicated to improving the diagnosis, prevention and treatment of osteoporosis. The Royal Osteoporosis Society offers support to people with osteoporosis and raises awareness of the importance of healthy bones. If you are concerned about osteoporosis, please contact the Royal Osteoporosis Society, Camerton, Bath BA2 0PJ. Tel: 01761 471 771, or email:[email protected]. *Registered Trademark
6
Calcichew-D3 1000 mg/800 IU Once Daily chewable tablets comes as tablet containing 1000mg / 800iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Calcichew-D3 1000 mg/800 IU Once Daily chewable tablets is calcium carbonate, colecalciferol; cholecalciferol.
This leaflet reproduces the patient information leaflet approved for Calcichew-D3 1000 mg/800 IU Once Daily chewable tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Prevention and treatment of vitamin D and calcium deficiency in adults with an identified risk.
Vitamin D and calcium supplement as an adjunct to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency.
Posology
Adults, including elderly
One tablet, once daily.
Special Patient Populations
Paediatric population:
Calcichew-D3 Once Daily is not intended for use in children and adolescents.
Impaired renal function
Calcichew-D3 Once Daily chewable tablets should not be used in patients with severe renal impairment (see section 4.3).
Impaired hepatic function:
No dose adjustment is required.
Method of Administration
Oral. The tablet should be chewed or sucked.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1
• Severe renal impairment (glomerular filtration rate < 30 ml/min/1.73m2)
• Diseases and/or conditions resulting in hypercalcaemia and/or hypercalcuria
• Renal calculi (nephrolithiasis)
• Hypervitaminosis D
During long-term treatment, serum calcium levels should be monitored. Renal function should also be monitored through measurements of serum creatinine. Monitoring is especially important in elderly patients on concomitant treatment with cardiac glycosides or diuretics (see section 4.5) and in patients with a high tendency to calculus formation. In case of hypercalcaemia or signs of impaired renal function the dose should be reduced or the treatment discontinued.
Calcium carbonate with cholecalciferol tablets should be used with caution in patients with hypercalcaemia or signs of impaired renal function and the effect on calcium and phosphate levels should be monitored. The risk of soft tissue calcification should be taken into account.
During concomitant treatment with other sources of vitamin D and/or medications or nutrients (such as milk) containing calcium, there is a risk of hypercalcaemia and milk-alkali syndrome with subsequent kidney function impairment. In these patients, serum calcium levels and renal function should be monitored.
Calcichew-D3 Once Daily chewable tablets should be prescribed with caution to patients suffering from sarcoidosis, due to the risk of increased metabolism of vitamin D into its active form. These patients should be monitored with regard to the calcium content in serum and urine.
Calcichew-D3 Once Daily chewable tablets should be used cautiously in immobilised patients with osteoporosis due to increased risk of hypercalcaemia.
Calcichew-D3 Once Daily contains and sucrose, which may be harmful to the teeth. The tablet also contains isomalt (E953). Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Calcichew-D3 Once Daily contains less than 23 mg sodium per tablet, that is to say essentially 'sodium-free'.
Thiazide diuretics reduce the urinary excretion of calcium, therefore, due to increased risk of hypercalcaemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics.
Calcium carbonate may interfere with the absorption of concomitantly administered tetracycline preparations. For this reason, tetracycline preparations should be administered at least two hours before or four to six hours after oral intake of calcium carbonate.
Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D. Patients should be monitored with regard to electrocardiogram (ECG) and serum calcium levels.
If a bisphosphonate is used concomitantly, this preparation should be administered at least one hour before the intake of Calcichew-D3 Once Daily chewable tablets since gastrointestinal absorption may be reduced.
The efficacy of levothyroxine can be reduced by the concurrent use of calcium, due to decreased levothyroxine absorption. Administration of calcium and levothyroxine should be separated by at least four hours.
The absorption of quinolone antibiotics may be impaired if administered concomitantly with calcium. Quinolone antibiotics should be taken two hours before or six hours after intake of calcium.
Calcium salts may decrease the absorption of iron, zinc and strontium ranelate. Consequently, iron, zinc or strontium ranelate preparations should be taken two hours before or after Calcichew-D3 Once Daily chewable tablets.
Treatment with orlistat may potentially impair the absorption of fat-soluble vitamins (e.g. vitamin D3).
Pregnancy
Calcichew-D3 Once Daily chewable tablets can be used during pregnancy, in case of a calcium and vitamin D deficiency. During pregnancy the daily intake should not exceed 2500 mg calcium and 4000 IU vitamin D. Studies in animals have shown reproductive toxicity of high doses of vitamin D (see section 5.3). In pregnant women, overdoses of calcium and vitamin D should be avoided as permanent hypercalcaemia has been related to adverse effects on the developing foetus. There are no indications that vitamin D at therapeutic doses is teratogenic in humans.
Breast-feeding
Calcichew-D3 Once Daily chewable tablets can be used during breast-feeding. Calcium and vitamin D3 pass into breast milk. This should be considered when giving additional vitamin D to the child.
Calcichew-D3 Once Daily chewable tablets have no known influence on ability to drive and use machines.
Adverse reactions are listed below, by system organ class and frequency. Frequencies are defined as: uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), or very rare (<1/10,000), or not known (cannot be estimated from the available data).
Immune system disorders
Not known: Hypersensitivity reactions such as angio-oedema or laryngeal oedema.
Metabolism and nutrition disorders
Uncommon: Hypercalcaemia and hypercalciuria.
Very rare: Milk-alkali syndrome (frequent urge to urinate; continuing headache; continuing loss of appetite; nausea or vomiting; unusual tiredness or weakness; hypercalcaemia, alkalosis and renal impairment). Seen usually only in overdose (see section 4.9).
Gastrointestinal disorders
Rare: Constipation, dyspepsia, flatulence, nausea, abdominal pain, and diarrhoea.
Skin and subcutaneous tissue disorders
Very rare: Pruritus, rash and urticaria.
Other special population
Patients with renal impairment: potential risk of hyperphosphatemia, nephrolithiasis and nephrocalcinosis. See section 4.4.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Overdose can lead to hypercalcaemia and hypervitaminosis D. Symptoms of hypercalcaemia may include anorexia, thirst, nausea, vomiting, constipation, abdominal pain, muscle weakness, fatigue, mental disturbances, polidipsia, polyuria, bone pain, nephrocalcinosis, renal calculi and in severe cases, cardiac arrhythmias. Extreme hypercalcaemia may result in coma and death. Persistently high calcium levels may lead to irreversible renal damage and soft tissue calcification.
Milk-alkali syndrome may occur in patients who ingest large amounts of calcium and absorbable alkali.
Treatment of hypercalcaemia
Treatment is essentially symptomatic and supportive. The treatment with calcium and vitamin D must be discontinued. Treatment with thiazide diuretics, and cardiac glycosides must also be discontinued (see section 4.5). Emptying of the stomach in patients with impaired consciousness. Rehydration, and, according to severity, isolated or combined treatment with loop diuretics, bisphosphonates, calcitonin and corticosteroids. Serum electrolytes, renal function and diuresis must be monitored. In severe cases, ECG and CVP should be followed.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Calcium carbonate, Colecalciferol; cholecalciferol. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Calcium carbonate, Colecalciferol; cholecalciferol. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Calcichew-D3 1000 mg/800 IU Once Daily chewable tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.